{
    "organizations": [],
    "uuid": "90b00b13d2359c0138ff3e55367ae63bf3c45b3c",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-neovacs-obtains-us-patent-for-trea/brief-neovacs-obtains-u-s-patent-for-treatment-of-interpheron-alpha-related-conditions-idUSFWN1QC01C",
    "ord_in_thread": 0,
    "title": "BRIEF-Neovacs Obtains U.S. Patent For Treatment Of Interpheron Alpha Related Conditions​",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 22 (Reuters) - NEOVACS SA:\n* ‍HAS BEEN GRANTED BY UNITED STATES PATENT AND TRADEMARK OFFICE (USPTO) A PATENT ​\n* ‍PATENT ENTITLED “METHOD FOR TREATING INTERPHERON ALPHA RELATED CONDITIONS”​\n* ‍ASSURES IN THIS COUNTRY PROTECTION OF ITS TECHNOLOGY PLATFORM AT LEAST UNTIL 2032​\n* ‍RESULTS OF PHASE IIB TRIAL IN LUPUS WITH THE IFN KINOID SHOULD BE COMMUNICATED BY JUNE THIS YEAR​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-02-22T14:51:00.000+02:00",
    "crawled": "2018-02-23T15:51:05.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "neovacs",
        "sa",
        "granted",
        "united",
        "state",
        "patent",
        "trademark",
        "office",
        "uspto",
        "patent",
        "entitled",
        "method",
        "treating",
        "interpheron",
        "alpha",
        "related",
        "condition",
        "country",
        "protection",
        "technology",
        "platform",
        "least",
        "phase",
        "iib",
        "trial",
        "lupus",
        "ifn",
        "kinoid",
        "communicated",
        "june",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}